Adverse reactions to vaccines

Annals of Allergy, Asthma and Immunology

Volumn 103, Issue 4 SUPPL. 2, 2009, Pages

  Kelso, John M ^a   Li, James T ^b   Nicklas, Richard A ^f   Blessing Moore, Joann ^c   Cox, Linda ^d   Lang, David M ^e   Oppenheimer, John ^g   Portnoy, Jay M ^h   Randolph, Christopher ⁱ   Schuller, Diane E ^j   Spector, Sheldon L ^k   Tilles, Stephen ^l   Wallace, Dana ^d   Ballas, Zuhair K ⁿ   Baker, James R ^m   Bellanti, Joseph A ^o   Ein, Daniel ^p   Grammer, Leslie C ^q  

^a SCRIPPS CLINIC   (United States)

^b Mayo Clinic   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d NOVA SOUTHEASTERN UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^g RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

ⁱ WATERBURY HOSPITAL   (United States)

^j PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁿ UNIVERSITY OF IOWA   (United States)

^o GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^p GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA VACCINE; FLULAVAL; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; IXIARO; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; NEOMYCIN; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; RUBELLA VACCINE; TETANUS TOXOID; THIOMERSAL; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ADVERSE OUTCOME; ANAPHYLAXIS; ARTHRITIS; CLINICAL RESEARCH; CONTACT DERMATITIS; DELAYED HYPERSENSITIVITY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESEARCH; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNIZATION; INJECTION SITE REACTION; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN TEST; THROMBOCYTOPENIA; VACCINATION;

HUMANS; VACCINES;

EID: 70350323509     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60350-X     Document Type: Article

References (110)

1. Ten great public health achievements-United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999;48:241-243. (IV)
2. Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007;298:2155-2163. (III)
3. Centers for Disease Control and Prevention. Recommended Immunization Schedule for Persons Aged 0 Through 6 Years United States 2009. http://www.cdc.gov/vaccines/recs/schedules/downloads/child/2009/ 09-0-6yrs-schedule-pr.pdf. 2009. Accessed September 4, 2009. (IB)
4. Centers for Disease Control and Prevention. Recommended Immunization Schedule for Persons Aged 7 Through 18 Years United States 2009. http://www.cdc.gov/vaccines/recs/schedules/downloads/child/2009/ 09-7-18yrs-schedule-pr.pdf. 2009. Accessed September 4, 2009. (IB)
5. Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule United States 2009. http://www.cdc.gov/vaccines/recs/ schedules/downloads/adult/2009/adult-schedule.pdf. 2009. Accessed September 4, 2009. (IB)
6. Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA. 1999;282:47-53. (IIB)
7. Danovaro-Holliday MC, LeBaron CW, Allensworth C, et al. A large rubella outbreak with spread from the workplace to the community. JAMA. 2000;284:2733-2739. (IIB)
8. Update: outbreak of poliomyelitis-Dominican Republic and Haiti, 2000-2001. MMWR Morb Mortal Wkly Rep. 2001;50:855- 856. (III)
9. Two fatal cases of adenovirus-related illness in previously healthy young adults-Illinois, 2000. MMWR Morb Mortal Wkly Rep. 2001;50: 553-555. (III)
10. Jansen VA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science. 2003;301:804. (IIB)
11. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK, Advisory Committee on Immunization Practices Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006;55:1- 48. (IV)
12. Vaccine Excipient and Media Summary, by Excipient. In: Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. Centers for Disease Control and Prevention: Epidemiology and Prevention of Vaccine-Preventable Diseases. 11th ed. Washington, DC: Public Health Foundation; 2009. (III)
13. Rietschel RL, Bernier R. Neomycin sensitivity and the MMR vaccine. JAMA. 1981;245:571. (IV)
14. Elliman D, Dhanraj B. Safe MMR vaccination despite neomycin allergy. Lancet. 1991;337:365. (IV)
15. Cox NH, Forsyth A. Thiomersal allergy and vaccination reactions. Contact Dermatitis. 1988;18:229 -233. (III)
16. Rietschel RL, Adams RM. Reactions to thimerosal in hepatitis B vaccines. Dermatol Clin. 1990;8:161-164. (IV)
17. Noel I, Galloway A, Ive FA. Hypersensitivity to thiomersal in hepatitis B vaccine. Lancet. 1991;338:705. (IV)
18. Aberer W. Vaccination despite thimerosal sensitivity. Contact Dermatitis. 1991;24:6 -10. (IIB)
19. Audicana MT, Munoz D, del Pozo MD, Fernandez E, Gastaminza G, Fernandez de Corres L. Allergic contact dermatitis from mercury antiseptics and derivatives: study protocol of tolerance to intramuscular injections of thimerosal. Am J Contact Dermatitis. 2002;13:3-9. (IIB)
20. Patrizi A, Rizzoli L, Vincenzi C, Trevisi P, Tosti A. Sensitization to thimerosal in atopic children. Contact Dermatitis. 1999;40:94 -97. (IV)
21. Lee-Wong M, Resnick D, Chong K. A generalized reaction to thimerosal from an influenza vaccine. Ann Allergy Asthma Immunol. 2005; 94:90 -94. (IV)
22. Kaaber K, Nielsen AO, Veien NK. Vaccination granulomas and aluminium allergy: course and prognostic factors. Contact Dermatitis. 1992;26:304 -306. (III)
23. Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine. 2003;22:64-69. (III)
24. Lehman HK, Faden HS, Fang YV, Ballow M. A case of recurrent sterile abscesses following vaccination: delayed hypersensitivity to aluminum. J Pediatr. 2008;152:133-135. (IV)
25. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112: 815-820. (IIB)
26. Stratton KH, Johnston RB. Adverse Events Associated With Childhood Vaccines: Evidence Bearing on Causality. Washington, DC: National Academy Press; 1994. (IIA)
27. Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 1994;12:542-550. (IV)
28. Vaccine Adverse Event Reporting System (VAERS). www.vaers.hhs.gov. Accessed September 4, 2009. (IV)
29. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001;20:63-75. (IIB)
30. Fiore AE, Feinstone SM, Bell BP. Hepatitis A vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia, PA: Elsevier; 2008. (IIB)
31. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 11th ed. Washington, DC: Public Health Foundation; 2009. (IIB)
32. Strebel PM, Papania MJ, Dayan GH, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia, PA: Elsevier; 2008. (IIB)
33. Plotkin SA, Vidor E. Poliovirus vaccine-inactivated. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia, PA: Elsevier; 2008. (IIB)
34. Plotkin SA, Koprowski H, Rupprecht CE. Rabies vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia, PA: Elsevier; 2008. (IIB)
35. Kelso JM. Adverse reactions to vaccines for infectious diseases. In: Adkinson NF, Bochner BS, Busse WW, Holgate ST, Lemanske RF, Simons FER, eds. Middleton's Allergy: Principles & Practice. 7th ed. Philadelphia, PA: Mosby; 2008:1189 -1204. (IIB)
36. Wood RA, Berger M, Dreskin SC, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008;122:e771-7. (IIB)
37. Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol. 1993;91:867- 872. (IV)
38. Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol. 1996;98:1058 -1061. (IIA)
39. Sakaguchi M, Yamanaka T, Ikeda K, et al. IgE-mediated systemic reactions to gelatin included in the varicella vaccine. J Allergy Clin Immunol. 1997;99:263-264. (IIA)
40. Sakaguchi M, Miyazawa H, Inouye S. Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines. Allergy. 2001;56:536 -539. (IIA)
41. Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J Allergy Clin Immunol. 2000;106:591-592. (III)
42. Zent O, Hennig R. Post-marketing surveillance of immediate allergic reactions: polygeline-based versus polygeline-free pediatric TBE vaccine. Vaccine. 2004;23:579 -584. (IIB)
43. O'Brien TC, Maloney CJ, Tauraso NM. Quantitation of residual host protein in chicken embryo-derived vaccines by radial immunodiffusion. Appl Microbiol. 1971;21:780 -782. (III)
44. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med. 1995;332:1262-1266. (IIB)
45. Baxter DN. Measles immunization in children with a history of egg allergy. Vaccine. 1996;14:131-134. (IIB)
46. Red Book: Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009. (IIA)
47. James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr. 1998;133: 624-628. (IIB)
48. Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol. 2002;110:834-840. (IIA)
49. Kelso JM. Raw egg allergy-a potential issue in vaccine allergy. J Allergy Clin Immunol. 2000;106:990. (IV)
50. Kelso JM, Cockrell GE, Helm RM, Burks AW. Common allergens in avian meats. J Allergy Clin Immunol. 1999;104:202-204. (IV)
51. DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J, Team VAERS. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine. 2006;24:703-707. (III)
52. GARDASIL: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant [package insert]. 2008. (III)
53. Lear JT, English JS. Anaphylaxis after hepatitis B vaccination. Lancet. 1995;345:1249. (IV)
54. Russell M, Pool V, Kelso JM, Tomazic-Jezic VJ. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2004;23:664-667. (III)
55. Latex in vaccine packaging In: Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. Centers for Disease Control and Prevention: Epidemiology and Prevention of Vaccine-Preventable Diseases. 11th ed. Washington, DC: Public Health Foundation; 2009. (IIB)
56. Kwittken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy. AJDC. 1993;147:128 -129. (IV)
57. Zheng W, Dreskin SC. Thimerosal in influenza vaccine: an immediate hypersensitivity reaction. Ann Allergy Asthma Immunol. 2007;99: 574-575. (IV)
58. Vaccine Excipient and Media Summary, by Vaccine. In: Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. Centers for Disease Control and Prevention: Epidemiology and Prevention of Vaccine-Preventable Diseases. 11th ed. Washington, DC: Public Health Foundation; 2009. (IIB)
59. Wood RA, Setse R, Halsey N. Irritant skin test reactions to common vaccines. J Allergy Clin Immunol. 2007;120:478-481. (III)
60. Nagel JE, White C, Lin MS, Fireman P. IgE synthesis in man, II: comparison of tetanus and diphtheria IgE antibody in allergic and nonallergic children. J Allergy Clin Immunol. 1979;63:308 -314. (IIA)
61. Edelman K, Malmstrom K, He Q, Savolainen J, Terho EO, Mertsola J. Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization. Eur J Pediatr. 1999;158: 989-994. (IIB)
62. Aalberse RC, van Ree R, Danneman A, Wahn U. IgE antibodies to tetanus toxoid in relation to atopy. Int Arch Allergy Immunol. 1995; 107:169 -171. (IIB)
63. Anolik R, Spiegel W, Posner M, Jakabovics E. Influenza vaccine testing in egg sensitive patients. Ann Allergy Asthma Immunol. 1992; 68:69. (III)
64. Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100: S1-148. (IIB)
65. Fasano MB, Wood RA, Cooke SK, Sampson HA. Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine. J Pediatr. 1992;120:878-881. (IIB)
66. Murphy KR, Strunk RC. Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins. J Pediatr. 1985;106: 931-933. (III)
67. YF-VAX (Sanofi Pasteur) [package insert]. In: Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2008. (IV)
68. Carey AB, Meltzer EO. Diagnosis and "desensitization" in tetanus vaccine hypersensitivity. Ann Allergy. 1992;69:336 -338. (IV)
69. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57:1- 60. (IIA)
70. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998;339:1797-1802. (IIA)
71. Sivadon-Tardy V, Orlikowski D, Porcher R, et al. Guillain-Barre syndrome and influenza virus infection. Clin Infect Dis. 2009;48: 48-56. (IIB)
72. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barre syndrome following influenza vaccination. JAMA. 2004;292:2478 -2481. (III)
73. Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine. 2007;25:5253-5255. (III)
74. Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reactions, contraindications, and precautions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1996;45:1-35. (IIB)
75. Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001;345:656-661. (IIB)
76. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA. 2004;292:351-357. (IIB)
77. Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J. 1996;15:88 -90. (III)
78. Jadavji T, Scheifele D, Halperin S. Thrombocytopenia after immunization of Canadian children, 1992 to 2001. Pediatr Infect Dis J. 2003;22:119 -122. (IIB)
79. Howson CP, Fineberg HV. Adverse events following pertussis and rubella vaccines: summary of a report of the Institute of Medicine. JAMA. 1992;267:392-396. (IIA)
80. Plotkin SA, Reef SE. Rubella vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia, PA: Elsevier; 2008. (IIB)
81. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981;68:650-660. (IB)
82. DuVernoy TS, Braun MM. Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998. Pediatrics. 2000;106:E52. (III)
83. Heijbel H, Ciofi degli Atti MC, Harzer E, et al. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies. Dev Biol Standardization. 1997;89:101-103. (IIA)
84. Le Saux N, Barrowman NJ, Moore DL, et al. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics. 2003;112:e348. (IB)
85. Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine: a postmarketing assessment. Arch Pediatr Adolesc Med. 1996;150:457- 460. (IIA)
86. Edwards KM, Decker MD. Pertussis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia, PA: Elsevier; 2008. (IIB)
87. Zielinski A, Rosinska M. Comparison of adverse effects following immunization with vaccine containing whole-cell vs. acellular pertussis components. Przegl Epidemiol. 2008;62:589 -596. (IIA)
88. Wassilak SGF, Roper MH, Kretsinger K, Orenstein WA. Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia, PA: Elsevier; 2008. (IIB)
89. Gershon AA, Takahashi M, Seward JF. Varicella vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia, PA: Elsevier; 2008. (IIB)
90. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA. 2000;284:1271-1279. (III)
91. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2000;19:916 -923. (III)
92. Kreth HW, Hoeger PH, Members of the VZVADsg. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. Eur J Pediatr. 2006;165:677- 683. (IIB)
93. Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, ed. Vaccines. Philadelphia, PA: Elsevier; 2008. (IIB)
94. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358:91-97. (IV)
95. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 2001;358:121-122. (IV)
96. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;358:98 -104. (IV)
97. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. MMWR Morb Mortal Wkly Rep. 2002;51:989 -993. (IV)
98. Doblas A, Domingo C, Bae HG, et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol. 2006;36: 156-158. (IV)
99. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077- 6082. (III)
100. Centers for Disease Control and Prevention. Guidelines for Vaccinating Pregnant Women from Recommendations of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: Centers for Disease Control and Prevention; 2007. (IIB)
101. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ. 2003;81:61-70. (IV)
102. Koppen S, de Groot R, Neijens HJ, Nagelkerke N, van Eden W, Rumke HC. No epidemiological evidence for infant vaccinations to cause allergic disease. Vaccine. 2004;22:3375-3385. (IIA)
103. Stratton K, Gable A, Shetty P. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: National Academy Press; 2001. (IIA)
104. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347:1477-1482. (IIB)
105. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S, Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med. 2001;344:319 -326. (IIB)
106. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60:504 -509. (IIA)
107. Food and Drug Administration. Thimerosal in Vaccines. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ UCM096228.htm 2009. Accessed September 4, 2009. (IIB)
108. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics. 2004;114:793- 804. (IIB)
109. RabAvert Rabies Vaccine (Chiron) [package insert]. 2004. (IV)
110. Kelso JM, Yunginger JW. Immunization of egg-allergic individuals with egg- or chicken-derived vaccines. Immunol Allergy Clin North Am. 2003;23:635- 648. (IIB))